 Inhibitors Market.webp)
BCL-2 (B-cell lymphoma 2) Inhibitors Market size is poised to reach USD 10 Billion by the end of 2036, growing at a CAGR of 14% during the forecast period, i.e., 2024 – 2036. In the year 2023, the industry size of BCL-2 (B-cell lymphoma 2) inhibitors was USD 2 Billion. The reason behind the growth is due to the rising cases of Diffuse B-cell Lymphoma. BCL-2 inhibitors are used in combination with other therapies such as chemotherapy for the treatment of Diffuse B-cell Lymphoma. Every year, more than 16,000 people are diagnosed with Diffuse B-cell Lymphoma around the globe.
The growing government initiatives are believed to fuel the BCL-2 inhibitors market growth. The governments of various regions have stated their intention to address the rising cancer burden by improving early cancer detection and treatment. This has created awareness among people across the globe for the early diagnosis of cancer, leading to higher demand for effective treatment including BCL-2 inhibitors. For instance, The World Health Organisation has recently launched the worldwide Breast Cancer Initiative, to reduce worldwide breast cancer mortality by 2.5% each year until 2040.
Growth Drivers
Challenges
|
Base Year |
2023 |
|
Forecast Year |
2024-2036 |
|
CAGR |
~14% |
|
Base Year Market Size (2023) |
~ USD 2 Billion |
|
Forecast Year Market Size (2036) |
~ USD 10 Billion |
|
Regional Scope |
|
Product (Combination Therapy, Monotherapy)
The combination therapy segment is estimated to hold 55% share of the global BCL-2 (B-cell lymphoma 2) inhibitors market in the coming years. Combination therapies are superior to monotherapy for many malignancies, as they provide a way to streamline complex treatment regimens, enhance treatment outcomes, and yield improved therapeutic effects, particularly when synergistic anticancer activity is obtained.
Combination therapy increases responses in a larger group of patients and also has the potential to diminish drug resistance while also offering therapeutic anti-cancer advantages. For instance, venetoclax is an investigational medicine that kills cancer cells by inhibiting a protein that has been used in a variety of treatment regimens, including chemotherapy, immunotherapy, and targeted therapies and appears to be a viable alternative for young relapsed/refractory AML patients.
Application (Cancer, Auto-immune diseases)
BCL-2 inhibitors market from the cancer segment is set to garner a notable share shortly. BCL-2 has been intensively explored in cancer, and recently, several Bcl-2 protein family inhibitors have been produced in recent years that are overexpressed in cancer cells and may suppress pro-apoptotic signals, allowing the cancer cells to survive under stressful environments. For instance, Venetoclax is the first selective BCL2 inhibitor, as well as the first of a new class of anticancer drugs known as BH3-mimetics which is the most advanced in development and has demonstrated encouraging outcomes in a subset of myeloma patients. Besides this, Palcitoclax is a highly powerful Bcl-2 family protein antagonist that, like navitoclax, primarily targets the antiapoptotic proteins Bcl-2 and Bcl-xL which was created to lessen on-target platelet toxicity while preserving significant anticancer activity.
Type (Follicular Lymphoma, Positive Lymphoma, Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma (MCL), Diffuse Large B-cell Lymphoma (DLBCL))
The follicular lymphoma segment in the BCL-2 (B-cell lymphoma 2) inhibitors market is set to garner a significant share during the forecast timeframe. Follicular lymphoma is a type of non-Hodgkin's lymphoma that is a subtype of B-cell lymphoma which is the second most frequent kind of non-Hodgkin lymphoma (NHL) that involves white blood cells called lymphocytes and accounts for over 25% of all lymphomas that is developed when the body produces aberrant B-cells, follicular lymphoma develops. BCL2 mutations in follicular lymphoma are associated with activation-induced cytidine deaminase production, and they inhibit cancer growth by targeting signaling molecules or protein kinases.
Our in-depth analysis of the global BCL-2 inhibitors market includes the following segments:
|
Product |
|
|
Type |
|
|
Application |
|
|
End-User |
|
|
Stage |
|
North American Market Forecast
BCL-2 (B-cell lymphoma 2) inhibitors market in North America is predicted to account for the largest share of 56% by 2036 impelled by the increasing product approvals. For instance, in 2020, The Food and Drug Administration approved venetoclax (VENCLEXTA, AbbVie Inc., and Genentech Inc.) after it was granted accelerated approval for use in 2018. Furthermore, the recommended dose of venetoclax is determined by the combination regimen that can be used in combination with azacitidine, decitabine, or low-dose cytarabine (LDAC) for newly diagnosed acute myeloid leukemia (AML) in people 75 years of age or older.
European Market Statistics
The Europe BCL-2 inhibitors market is estimated to be the second largest, during the forecast timeframe led by increasing health awareness. Moreover, Europe has developed several innovative and effective solutions to promote good health and well-being, and to create awareness about the importance of healthy lifestyles. This, as a result, may drive demand for BCL-2 inhibitors for several diseases prevailing in the region.
 Inhibitors Market Size.webp)
Author Credits: Radhika Gupta, Shivam Bhutani
Copyright © 2024 Research Nester. All Rights Reserved
FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.
Have questions before ordering this report?